ライフサイエンスコーパス: insulin-sensitizing

1 ellular reactive oxygen species required for insulin sensitizing.

2 ocytes and the tissue-specific nature in the insulin sensitizing action of rosiglitazone, we examined

3 racellular Ca2+ handling, independent of its insulin sensitizing action.

4 tion of SIRT1 in adipocytes induces the same insulin-sensitizing action as PPARgamma ligands.

5 first evidence that thiazolidinediones exert insulin-sensitizing action directly on pancreatic beta-c

6 we have uncovered an unexpected, neomorphic insulin-sensitizing action for exogenous non-mitogenic h

7 one leptin has profound glucose-lowering and insulin-sensitizing action in type 1 diabetic rodent mod

8 P13 in adipocytes, which correlates with the insulin-sensitizing action of CTRP13.

9 the latter being largely independent of the insulin-sensitizing action of the drug.

10 e microvasculature, which contributes to its insulin-sensitizing action.

11 SHR model, Cd36 is a key determinant of the insulin-sensitizing actions of a thiazolidinedione ligan

12 In contrast to the insulin-sensitizing actions of adiponectin in liver and

13 the Cd36 fatty acid transporter gene in the insulin-sensitizing actions of thiazolidinediones, we st

14 on animal models to delineate the receptor's insulin-sensitizing actions.

15 thazolamide (MTZ) and related compounds with insulin sensitizing activity in vitro.

16 ntification of PPARgamma ligands with robust insulin-sensitizing activity and improved tolerance amon

17 thesis of new RXR modulators that retain the insulin-sensitizing activity of RXR agonists but produce

18 The insulin-sensitizing activity points to a more central ro

19 t in a manner that leads to retention of the insulin-sensitizing activity that is characteristic of f

20 believed that thiazolidinediones exert their insulin-sensitizing activity through activation of perox

21 igated the effect of iron on adiponectin, an insulin-sensitizing adipokine that is decreased in diabe

22 C1q/TNF-related protein-12 (CTRP12), a novel insulin-sensitizing adipokine that regulates glucose met

23 of Fam132a, which encodes a newly identified insulin-sensitizing adipokine, adipolin, is significantl

24 cluding a reduction in the expression of the insulin-sensitizing adipokine, adiponectin.

25 expression in beta-cells and Adiponectin, an insulin-sensitizing adipokine, in adipocytes; in vivo os

26 erminants of blood levels of adiponectin, an insulin-sensitizing adipokine.

27 n summary, glypican-4 is a novel circulating insulin sensitizing adipose-derived factor that, unlike

28 Troglitazone, an insulin sensitizing agent, reduces glucose concentration

29 We additionally hypothesized that an insulin-sensitizing agent (rosiglitazone) would prevent

30 hese results indicate that treatment with an insulin-sensitizing agent can lead to improvement in bio

31 This prospective study evaluates the role of insulin-sensitizing agent in treatment of NASH.

32 h returned to normal upon treatment with the insulin-sensitizing agent pioglitazone.

33 tazone, like other thiazolidinediones, is an insulin-sensitizing agent that activates the peroxisome

34 Rosiglitazone is an insulin-sensitizing agent that has recently been shown t

35 atment of normal (nondiabetic) pigs with the insulin-sensitizing agent troglitazone improves recovery

36 Troglitazone is a new insulin-sensitizing agent used to treat type 2 diabetes

37 Metformin is an insulin-sensitizing agent with potent antihyperglycemic

38 Farglitazar (GI262570), an insulin-sensitizing agent, selectively binds and activat

39 Troglitazone (TRO), a novel insulin-sensitizing agent, significantly lowers blood pr

40 s and then 4 mg twice daily for 8 weeks), an insulin-sensitizing agent, was given to 7 insulin-resist

41 primarily focused on weight loss and use of insulin sensitizing agents, including the thiazolidenedi

42 ediones, pioglitazone and rosiglitazone, are insulin sensitizing agents, that are licensed for the ma

43 the intracellular targets of a new class of insulin sensitizing agents, the thiazolidinediones.

44 Novel insulin sensitizing agents, thiazolidinediones, have bee

45 s have demonstrated the potential utility of insulin-sensitizing agents and lipid-lowering therapies

46 by thiazolidinediones (TZDs), widely used as insulin-sensitizing agents for the treatment of type 2 d

47 ith hyperinsulinemia and insulin-resistance, insulin-sensitizing agents might be beneficial.

48 ce all PPARgamma agonists were orally active insulin-sensitizing agents producing reductions of eleva

49 is and is the molecular target of a class of insulin-sensitizing agents used for the management of ty

50 iazolidinediones (TZDs) are a novel class of insulin-sensitizing agents used in the treatment of NIDD

51 estrogen-progestin oral contraceptives, (3) insulin-sensitizing agents, and (4) estrogen-progestin f

52 Newer therapies, such as insulin-sensitizing agents, are beneficial in correcting

53 compounds, as well as a subclass of non-TZD insulin-sensitizing agents, have been shown to be peroxi

54 ance that is distinct from commonly utilized insulin-sensitizing agents, the inhibitor promoted insul

55 A novel class of insulin-sensitizing agents, the thiazolidinedines (TZDs)

56 zone) and troglitazone are thiazolidinedione insulin-sensitizing agents, which are undergoing clinica

57 int to evaluate and perhaps develop improved insulin-sensitizing agents.

58 skewing differentiation of macrophages into insulin-sensitizing, alternatively activated M2 macropha

59 ega-3 FA receptor/sensor and mediates potent insulin sensitizing and antidiabetic effects in vivo by

60 s through lifestyle modifications as well as insulin sensitizing and antioxidant medications may be o

61 iponectin, a vasculoprotective molecule with insulin-sensitizing and anti-atherogenic properties, sup

62 Adiponectin is an insulin-sensitizing and anti-inflammatory fat cell hormo

63 Despite extensive documentation of their insulin-sensitizing and antihyperglycemic effects, the i

64 xisome proliferator-activated receptors with insulin-sensitizing and glucose-lowering actions and fav

65 t strategies for treatment of hyperglycemia, insulin-sensitizing and insulin-providing strategies, on

66 ss-induced hormone with potent anti-obesity, insulin-sensitizing, and hepatoprotective properties.

67 Insulin sensitizing, anti-inflammatory, and antifibrotic

68 Adiponectin is an adipokine with insulin-sensitizing, anti-inflammatory, and cardiac prot

69 a circulating adipocyte-derived protein, has insulin-sensitizing, anti-inflammatory, antiatherogenic,

70 been widely studied and shown to have potent insulin-sensitizing, antiapoptotic, and anti-inflammator

71 Adiponectin has insulin-sensitizing, antiatherogenic, and anti-inflammat

72 n actively pursued as the next generation of insulin-sensitizing antidiabetic drugs, because the curr

73 The thiazolidinedione class of insulin-sensitizing, antidiabetic drugs interacts with p

74 ectin, a hormone secreted by adipocytes, has insulin-sensitizing, antidiabetic, antiinflammatory, and

75 clinical studies, reveal the lipid-lowering, insulin-sensitizing, antihypertensive, and anti-inflamma

76 ormone secreted by adipose tissue that shows insulin-sensitizing, antiinflammatory, and antiatherogen

77 Metformin, an insulin-sensitizing biguanide, enhances peripheral insul

78 The insulin-sensitizing compound troglitazone has evolved in

79 he therapeutic potential of chiro-inositols, insulin-sensitizing compounds safe for human consumption

80 h that among the 12,069 treated with neither insulin-sensitizing drug (36.0%, P= or <0.0001 for both

81 his case, insulin resistance) and whether an insulin-sensitizing drug (metformin) is cardioprotective

82 ered as a binding target of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class

83 Our objective was to determine if the insulin-sensitizing drug pioglitazone acutely reduces in

84 infarction (MI) derive more benefit from the insulin-sensitizing drug pioglitazone hydrochloride comp

85 The insulin-sensitizing drug rosiglitazone also increases th

86 f insulin resistance in Zucker rats with the insulin-sensitizing drug rosiglitazone partially restore

87 were randomized to placebo (n = 133) or the insulin-sensitizing drug troglitazone (400 mg/day; n = 1

88 tection was potentiated by rosiglitazone, an insulin-sensitizing drug used to treat type 2 diabetes.

89 y investigates whether the widely prescribed insulin-sensitizing drug, metformin (Glucophage(R)), aff

90 Upon treatment with rosiglitazone, an insulin-sensitizing drug, these macrophage-originated ge

91 4 levels are normalized by rosiglitazone, an insulin-sensitizing drug.

92 the target of the thiazolidinedione class of insulin sensitizing drugs.

93 We investigated the effects of two insulin-sensitizing drugs (metformin and rosiglitazone)

94 Thiazolidinediones (TZDs) are insulin-sensitizing drugs and are potent agonists of the

95 The thiazolidinedione (TZD) insulin-sensitizing drugs and peroxisome proliferator-ac

96 bers of the thiazolidinedione (TZD) class of insulin-sensitizing drugs are extensively used in the tr

97 ggests that Gpr120 agonists could become new insulin-sensitizing drugs for the treatment of type 2 di

98 Insulin-sensitizing drugs of the thiazolidinedione class

99 PPARgamma is a target for insulin-sensitizing drugs such as glitazones, which impr

100 oved thiazolidinediones (TZDs) are effective insulin-sensitizing drugs that may have efficacy for tre

101 The insulin-sensitizing drugs thiazolidinediones (TZDs) are

102 ts, "such as thiazolidinediones-" a class of insulin-sensitizing drugs, have been reported to cause a

103 o the functional receptor for a new class of insulin-sensitizing drugs, the thiazolidinediones, now w

104 rget of the thiazolidinedione (TZD) class of insulin-sensitizing drugs, which have been widely prescr

105 se homeostasis, and is a molecular target of insulin-sensitizing drugs.

106 receptor for the thiazolidinedione class of insulin-sensitizing drugs.

107 receptor for the thiazolidinedione class of insulin-sensitizing drugs.

108 In obese subjects, this insulin-sensitizing effect could not be detected.

109 Harmine is a natural compound possessing insulin-sensitizing effect in db/db diabetic mice.

110 ted beta-oxidation in muscle cells exerts an insulin-sensitizing effect independently of changes in i

111 knockout mice, we demonstrate that the Sesn3 insulin-sensitizing effect is largely independent of AMP

112 This insulin-sensitizing effect is specific for GIP because i

113 sphorylation site (TSC2S1345A) inhibited the insulin-sensitizing effect of adiponectin in C2C12 cells

114 expression of LKB1 in HeLa cells rescued the insulin-sensitizing effect of adiponectin.

115 not dominant-negative p38 MAPK, reduced the insulin-sensitizing effect of adiponectin.

116 eptor substrate (IRS)-1 is essential for the insulin-sensitizing effect of CR, we measured in vitro 2

117 We conclude that the mechanism for the insulin-sensitizing effect of troglitazone, but not metf

118 A similar insulin-sensitizing effect was seen upon treatment of ob

119 The consequent insulin-sensitizing effect within skeletal muscle lowere

120 tance in mice while also having an opposite, insulin-sensitizing effect, accompanied by reduced tissu

121 a signaling is also required for the hepatic insulin sensitizing effects of TZDs.

122 O mice are refractory to both the beneficial insulin-sensitizing effects and the detrimental weight g

123 between adiponectin multimerization and its insulin-sensitizing effects has been demonstrated, sugge

124 betic thiazolidinediones (TZDs), which exert insulin-sensitizing effects in adipose tissue, skeletal

125 has attracted much attention because of its insulin-sensitizing effects in liver and skeletal muscle

126 These insulin-sensitizing effects in mice and human myotubes w

127 rapeutic target of the anti-inflammatory and insulin-sensitizing effects of AICAR.

128 s reveal novel mechanistic insights into the insulin-sensitizing effects of DGAT1 inhibition in mouse

129 largely unrelated to leptin action and that insulin-sensitizing effects of FABP deficiency are, at l

130 obesity are both likely to contribute to the insulin-sensitizing effects of regular physical activity

131 r 7 days and compared responses to the known insulin-sensitizing effects of rosiglitazone (6 mg kg(-1

132 studies are needed to determine whether the insulin-sensitizing effects of the glitazones can preven

133 lts further suggest the possibility that the insulin-sensitizing effects of the thiazolidinedione dru

134 ectin multimer may contribute to the hepatic insulin-sensitizing effects of these agents.

135 n sensitivity and this receptor mediates the insulin-sensitizing effects of thiazolidinediones (TZDs)

136 The insulin-sensitizing effects of thiazolidinediones are th

137 eptor-gamma; an action may contribute to the insulin-sensitizing effects of this class of compounds.

138 probably explained by the peripheral tissue insulin-sensitizing effects of troglitazone.

139 mega-3-FAs produce robust anti-inflammatory, insulin-sensitizing effects, both in vivo and in vitro,

140 addition to its potent glucose-lowering and insulin-sensitizing effects, rFGF1 could be therapeutica

141 ecreted by adipocytes and is thought to have insulin-sensitizing effects.

142 ycemic control through its peripheral tissue insulin-sensitizing effects.

143 in vivo inhibition of Ltb4r1 leads to robust insulin-sensitizing effects.

144 s and diabetes, exerts anti-inflammatory and insulin-sensitizing effects.

145 , such as INT131 (1), have displayed similar insulin-sensitizing efficacy as TZDs, but lack many side

146 the absence of classical agonism, to derive insulin-sensitizing efficacy with improved therapeutic i

147 ng and provide a molecular mechanism for the insulin sensitizing function of adiponectin.

148 genes and increasing adipocyte expression of insulin-sensitizing genes.

149 The insulin sensitizing glitazone drugs, rosiglitazone (ROS)

150 in signaling and thus affect activity of the insulin-sensitizing hormone osteocalcin.

151 Adiponectin (Acrp30) is an insulin-sensitizing hormone produced and secreted exclus

152 Adiponectin is a circulating insulin-sensitizing hormone that homooligomerizes into t

153 Adiponectin, an insulin-sensitizing hormone, and resistin, known to prom

154 es to prevent type 2 diabetes might focus on insulin-sensitizing interventions rather than interventi

155 related to the production and release of the insulin-sensitizing lipokine palmitoleate (16:1n-7).

156 multimer of adiponectin may be an important insulin-sensitizing mechanism.

157 d through both an insulin-independent and an insulin-sensitizing mechanism.

158 ed into those using TZDs and those not using insulin-sensitizing medication based on prescriptions fi

159 ZDs and 1,192 (25.4%) patients not receiving insulin-sensitizing medications died (adjusted hazard ra

160 TZDs and 741 (15.8%) patients not receiving insulin-sensitizing medications required HF hospitalizat

161 ality when compared with those not receiving insulin-sensitizing medications.

162 Adiponectin is a major insulin-sensitizing, multimeric hormone derived from adi

163 trials, NASH was partially attenuated by an insulin-sensitizing peroxisome proliferator-activated re

164 at evoke fewer side effects while preserving insulin-sensitizing potential.

165 es (TZDs) pioglitazone and rosiglitazone are insulin-sensitizing PPARgamma agonists used to treat typ

166 one with anti-atherogenic, anti-diabetic and insulin sensitizing properties.

167 thiazolidenediones, which are compounds with insulin-sensitizing properties in several tissues, inclu

168 plasma protein with anti-atherosclerotic and insulin-sensitizing properties that suppresses hepatic g

169 the treatment of diabetes mellitus for their insulin-sensitizing properties, but also have immunomodu

170 pocyte-derived hormone with antidiabetic and insulin-sensitizing properties.

171 tin, an adipokine with anti-inflammatory and insulin-sensitizing properties.

172 Because adiponectin is suspected to have insulin-sensitizing proprieties, these epigenetic adapta

173 trast to the insulin-providing strategy, the insulin-sensitizing strategy led to (1) lower plasma ins

174 rator activated receptor gamma, are one such insulin-sensitizing therapeutic intervention in current

175 T2D and raise the possibility of developing insulin-sensitizing therapeutics based on manipulations

176 is might be a useful approach for developing insulin-sensitizing therapeutics.

177 atosis and bone loss associated with current insulin-sensitizing therapies.

178 is mechanism could lead to a new approach to insulin-sensitizing therapies.

179 Therefore, early administration of insulin-sensitizing therapy may reduce breast cancer ris

180 Insulin-sensitizing therapy mitigates the reproductive d

181 ns are increased in 3T3-L1 adipocytes by the insulin sensitizing thiazolidinedione drugs, which are a

182 Insulin-sensitizing thiazolidinedione (TZD) compounds ar

183 ma (PPARgamma) ligands, namely the synthetic insulin-sensitizing thiazolidinedione (TZD) compounds, h

184 The insulin-sensitizing thiazolidinedione pioglitazone resto

185 Insulin-sensitizing thiazolidinedione therapy normalized

186 Binding of pioglitazone, an insulin-sensitizing thiazolidinedione used in the treatm

187 Troglitazone is an insulin-sensitizing thiazolidinedione, which improves he

188 ptor-gamma (PPAR-gamma) is the target of the insulin sensitizing thiazolidinediones (TZDs), a class o

189 eptor (PPAR) gamma, the molecular target for insulin sensitizing thiazolidinediones used in patients

190 AR ligands such as fibrates (PPAR-alpha) and insulin-sensitizing thiazolidinediones (PPAR-gamma) are

191 inding certain fatty acids, eicosanoids, and insulin-sensitizing thiazolidinediones (TZD).

192 s activated by fatty acids, eicosanoids, and insulin-sensitizing thiazolidinediones (TZDs).

193 Insulin-sensitizing thiazolidinediones have shown effica

194 e CD40L (sCD40L) and that treatment with the insulin-sensitizing thiazolidinediones lowers this index

195 was elevated in obese mice and decreased by insulin-sensitizing thiazolidinediones.

196 Insulin-sensitizing treatment is sufficient to abrogate

197 t potential benefits of anti-inflammatory or insulin-sensitizing treatment strategies in healthy indi

198 The insulin-sensitizing treatment strategy led to changes in

199 arization versus initial medical therapy and insulin-sensitizing versus insulin-providing therapy on

200 PPARgamma ligands such as rosiglitazone are insulin sensitizing, yet the mechanisms remain unclear.